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Despite advances in wound care, many wounds never heal and become chronic problems
that result in significant morbidity and mortality to the patient. Cellular therapy for
cutaneous wounds has recently come under investigation as a potential treatment
modality for impaired wound healing. Bone marrow-derived mesenchymal stem cells
(MSCs) are a promising source of adult progenitor cells for cytotherapy as they are easy to
isolate and expand and have been shown to differentiate into various cell lineages. Early
studies have demonstrated that MSCs may enhance epithelialization, granulation tissue
formation, and neovascularization resulting in accelerated wound closure. It is currently
unclear if these effects are mediated through cellular differentiation or by secretion of
cytokines and growth factors. This review discusses the proposed biological contributions
of MSCs to cutaneous repair and their clinical potential in cell-based therapies.
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INTRODUCTION
Chronic wounds are a cause of significant morbidity and mor-
tality and pose a large financial burden on the healthcare sys-
tem. Proper cutaneous wound repair requires a well-coordinated
response of inflammation, neovascularization, extracellular
matrix formation, and epithelialization. Failure of any of these
processes due to ischemia, reperfusion injury, bacterial infection,
or aging can result in chronic inflammation and a non-healing
wound (Mustoe et al., 2006).
Traditional therapies for the treatment of chronic wounds
include debridement, minimization of bacterial load, pressure
offloading, negative-pressure therapy, biological dressings, skin
grafting, and reconstructive tissue flaps. Despite the most recent
advances in wound management, up to 50% of chronic wounds
still fail to heal (Cha and Falanga, 2007). One hypothesis for
this problem is that resident cells in non-healing wounds are
intrinsically impaired and demonstrate increased senescence and
decreased response to growth factors (Hasan et al., 1997; Vande
Berg et al., 1998).
Bone marrow-derived mesenchymal stem cells (MSCs) were
originally described as plastic-adherent fibroblast-like cells and
can differentiate into osteoblasts, adipocytes, and chondrocytes
(Friedenstein et al., 1976; Pittenger et al., 1999). Their plasticity
has since been expanded to include contribution to cell lineages
in brain (Brazelton et al., 2000), muscle (Ferrari et al., 1998), liver
(Alison et al., 2000), and kidney tissue (Poulsom et al., 2001).
MSCs are easy to isolate and expand in culture and studies have
suggested minimal immunogenic response when allogeneic or
syngeneic cells are used (Ryan et al., 2005; Chen et al., 2009).
Given these qualities and the current barriers limiting embryonic
stem cell research, MSCs have become a recent focus of interest for
cellular therapy in tissue regeneration. The application of MSCs
for tissue repair has ranged from intravenous infusion to reduce
the size of brain infarcts in a rat stroke model (Li et al., 2005) to
implantation of cells in the myocardium to reduce left ventricu-
lar dysfunction in a swine model of myocardial ischemia (Amado
et al., 2005). Here we review the existing evidence for MSC-based
therapies for cutaneous wound healing and future directions to
bring their potential to the clinical setting.
BONE MARROW-DERIVED CELLS IN NORMAL
POST-NATAL SKIN DEVELOPMENT
Early literature demonstrating the contribution of bone-marrow
derived cells to the epidermis formed the basis for investigat-
ing the role for BM-MSCs specifically in cutaneous repair. The
development of transgenic mice strains expressing green fluores-
cent protein (GFP) has been essential in allowing investigators
to understand the behavior of cells in vivo. When coupled with
bone marrow transplantation or parabiosis models, GFP+ donor
cells can be identified in wild-type mice using basic immunohis-
tochemistry techniques to track cellular fate and differentiation.
The ability for precursor cells to mobilize from the bone marrow
niche to peripheral tissue remains controversial, however, several
investigators have demonstrated the existence of circulating bone
marrow precursor cell (Roufosse et al., 2004). Several early ani-
mal studies have reported that in normal skin homeostasis, bone
marrow-derived cells may contribute to keratinocytes in the epi-
dermis and sebaceous glands as well as dendritic cells within the
dermis. The aggregate contribution to the epidermis and dermis
by cells of bone marrow origin has been described as 11–14%
of the total cell population (Fathke et al., 2004; Deng et al.,
2005). Cell fusion between bonemarrow-derived cells andmature
resident cells has been observed in in vitro co-culture systems
by several groups resulting in cells that adapt a “differentiated”
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phenotype but fail to undergo true differentiation (Terada et al.,
2002; Spees et al., 2003). Several investigators have attempted
to address this phenomenon and have demonstrated a lack of
cell fusion in these models by using sex-mismatched donor cells
and performing FISH analysis (Brittan et al., 2005; Wu et al.,
2007; Sasaki et al., 2008). In a similar model, Badiavas et al.
utilized a total bone marrow transplantation model and discov-
ered bone marrow-derived CD34+ (a hematopoietic stem cell
marker) keratinocytes in the hair bulge region which is thought
to be the stem cell niche for epidermal stem cells (Badiavas et al.,
2003; Trempus et al., 2003). This suggests that potentially cir-
culating bone marrow-derived cells may serve to replenish the
epithelial stem cell compartment throughout life. While still early,
these studies highlight the potential role of bone marrow-derived
stem cells in differentiating into various lineages to maintain skin
homeostasis.
MSC DELIVERY ENHANCES CUTANEOUSWOUND REPAIR
Wound healing studies have subsequently focused onMSCs as the
potential cell population within bone marrow that can contribute
to cutaneous regeneration. Studies in both mice and humans
have consistently demonstrated enhanced wound repair following
treatment with bone marrow-derived MSCs (Table 1).
The use of murine models has been crucial for advancing the
understating of wound healing, however, fundamental differences
exist between themouse and human skin.Murine skin lacks apoc-
rine sweat glands and rete ridges/dermal papillae, which are both
found in human skin. However, rete ridge-like structures may
become apparent during mouse wound healing and are often
described as “pseudoepitheliomatous” or “pseudocarcinomatous
hyperplasia” (Sundberg, 2004). Mouse skin also has a panniculo-
sus carnosus layer, a thin subcutaneous muscle layer only found
in the human neck (platysma). This muscle layer produces rapid
wound contraction following injury which is the primarymethod
of wound healing in the mouse as opposed to granulation tis-
sue formation and re-epithelialization in humans.Mouse skin has
also been shown to be thinner and more compliant than human
skin (Aarabi et al., 2007). A more complete summary of murine
wound healing models is reviewed here (Wong et al., 2011b).
Experiments with diabetic murine models have been partic-
ularly useful in assessing the clinical utility of MSCs in wound
repair. Many non-healing ulcers are caused by diabetic pathology
which has been shown to attenuate the recruitment of inflam-
matory cells and down-regulate expression of various growth
factors (Falanga, 2005). Local delivery of MSCs significantly
increased granulation tissue formation and decreased wound
healing time in leptin receptor-deficient db/db diabetic mice
compared to those treated with either PBS or non-cell type-
specific bone marrow aspirate (Javazon et al., 2007). Analysis
of the mechanical properties of treated wounds revealed that
administration of MSCs not only accelerated wound closure but
also enhanced wound repair quality, resulting in healed tissue
with increased tensile strength. This effect is thought to be sec-
ondary to increased collagen composition within the healed tissue
(McFarlin et al., 2006; Kwon et al., 2008). The mechanism for
this observed increase in collagen secretion is currently under
investigation.
Promising findings in animal models have led to a very lim-
ited number of small-scale human trials examining the effects of
autologous MSCs on chronic wounds. Injection of primary bone
marrow cells into the wound edge followed by topical application
of culturedMSCs resulted in the complete closure of three chronic
wounds which had failed traditional therapy including autolo-
gous skin grafting (Badiavas and Falanga, 2003). Hallmarks of the
healing wounds were a massive influx of mature and immature
inflammatory cells, increased vascularity, and increased dermal
thickness. It must be noted that this study utilized the injec-
tion of whole bone marrow aspirate which includes a large and
mixed population of hematopoietic stem cells and inflammatory
cells.
Dash et al. conducted the only randomized controlled trial
investigating the use of MSCs in 24 patients with non-healing
lower extremity ulcers secondary to diabetes or vasculitis.
Autologous MSCs expanded in culture were injected intramuscu-
larly into the wound edges of the treatment group. Twelve weeks
after implantation, ulcer size in the MSC-treated group decreased
73% while those receiving standard wound care only decreased
23%. In addition, subjects receiving MSC injections increased
their pain-free walking distance 7.5-fold compared to 2.2-fold in
the control group with no reported adverse effects (Dash et al.,
2009). Increased numbers of mature immune cells in the dermis
of wound biopsies in the treatment group suggest an augmented
inflammatory response as a possible mechanism for enhanced
repair.
MSCs ENHANCE WOUND HEALING BY DIFFERENTIATION
INTO EPIDERMAL CELLS
There is data to suggest that MSCs mobilize from the bone
marrow niche and traffic to ischemic tissue via the peripheral cir-
culation in response to cytokine signaling (Hamou et al., 2009).
Once at the site of injury, it is hypothesized that they contribute
to wound healing by differentiating into various cells of the
epidermis and dermis (Figure 1).
In culture, MSCs have been observed to differentiate into
K14+ keratinocytes when grown in the presence of the growth
factor BMP-4 (Sasaki et al., 2008). Histological examination of
murine wounds treated with GFP + MSCs has demonstrated
various levels of direct engraftment of donor cells into the epider-
mis as mature keratinocytes (Badiavas et al., 2003; Fathke et al.,
2004; Harris et al., 2004). There is also evidence that transplanted
MSCs are capable of ongoing differentiation as the percentage
of GFP+ keratinocytes increases when wounds are analyzed over
time. However, long-term engraftment has not been observed
(Wu et al., 2007). Furthermore, differentiated cells have been
observed to maintain active proliferation in vivo (Borue et al.,
2004).
MSCs ENHANCE NEOVASCULARIZATION DURING
WOUND REPAIR
New vessel formation, or neovascularization, is a critical com-
ponent of wound healing as it is necessary to supply oxygen
and nutrients to and carry waste away from the damaged tis-
sue. Neovascularization can occur by two mechanisms: angio-
genesis and vasculogenesis. During angiogenesis, tissue ischemia
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Table 1 | Study design and results for treatment of cutaneous wounds with mesenchymal stem cell therapy.
Species Wound type Therapy type Delivery method Control(s) Findings Reference
Mouse Excisional
wounds
Concentrated
conditioned
medium from
allogeneic P3
MSCs
Single
subcutaneous
injection of 80ul
and topical
application of
20 ul conditioned
medium
Concentrated
conditioned
medium from
dermal fibroblasts
Accelerated
wound closure.
Increased
recruitment of
macrophages and
endothelial
progenitor cells
Chen et al., 2008
Mouse Excisional
wounds
Allogeneic P3
MSCs
Single systemic
injection of
1× 106 cells
PBS Accelerated
wound healing Sasaki et al.,
2008
Mouse Excisional
wounds
Allogeneic P3-6
MSCs
Topical
application of
2.5× 105 cells
seeded on
hydrogel scaffold
No treatment,
hydrogen alone,
and intradermal
injection
Accelerated
wound healing.
Increased
angiogenesis and
restoration of hair
follicles and
sebaceous
glands.
Rustad et al.,
2012
Mouse (wild type
and diabetic)
Excisional
wounds
Allogeneic P3-5
MSCs
Single
intradermal
injection of
1× 106 cells
Dermal
fibroblasts
Accelerated
wound closure.
Increased
granulation
tissue,
angiogenesis,
and restoration of
hair follicles.
Wu et al., 2007
Mouse (diabetic) Excisional
wounds
Allogeneic P33
MSCs
Single topical
application of
7.5× 105 cells
PBS Accelerated
wound closure.
Increased
granulation tissue
and
angiogenesis.
Javazon et al.,
2007
Rat Incisional fascial
wounds
Allogeneic P3-5
MSCs
Four systemic
injections of
2× 106 cells OR.
Single
intradermal
injection of
6× 106 cells
PBS Increased wound
burst strength.
Increased
collagen
composition
McFarlin et al.,
2006
Rat (diabetic) Incisional fascial
wounds
Allogeneic P2-6
MSCs
Four systemic
injections of
1.5× 106 cells
OR. Single
intradermal
injection of
6× 106 cells
PBS Increased wound
burst strength.
Increased
collagen
composition
Kwon et al., 2008
Human Chronic
non-healing
wounds (n = 3)
Autologous bone
marrow aspirate
and cultured
MSCs
Subcutaneous
injection of bone
marrow aspirate
and 1–3 topical
applications of
MSCs
None Complete closure
of wounds.
Increased
inflammatory
response and
angiogenesis.
Badiavas and
Falanga, 2003
(Continued)
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Table 1 | Continued
Species Wound type Therapy type Delivery method Control(s) Findings Reference
Human Chronic
non-healing
wounds (n = 24)
Autologous P0
MSCs
Intramuscular and
subcutaneous
injection of > 1× 106
cells/cm2 ulcer area
and topical
application
Standard wound
care
Decreased wound
size. Increased
pain-free walking
distance
Dash et al., 2009
Human Acute (n = 4) and
chronic (n = 6)
non-healing
wounds
Autologous P2-10
MSCs
1–3 topical
applications by fibrin
spray
None Complete healing of
acute wounds.
Reduction or
complete closure of
chronic wounds.
Dose dependent
effect.
Falanga et al.,
2007
Human Chronic
non-healing
wounds (n = 20)
Autologous P0
MSCs
Topical application of
MSC seeded
collagen sponge
None Complete closure of
13 wounds. Partial
closure of five
wounds.
Yoshikawa et al.,
2008
MSC, mesenchymal stem cell; P, passage.
FIGURE 1 | Possible cell fate of mesenchymal stem cells in
cutaneous repair. In vitro studies have demonstrated that MSCs are
capable of differentiating into cells with keratinocytic, fibroblastic,
endothelial, and adipocytic phenotypes when cultured under
specific conditions. Several studies utilizing wound healing models and
transplanted labeled MSCs have provided evidence that
cellular differentiation occurs in vivo to contribute to cutaneous
repair.
initiates signals that stimulate mature resident endothelial cells
to proliferate and sprout new vessels (Folkman, 1995). In con-
trast, vasculogenesis involves the formation of de novo blood
vessels from circulating vascular progenitor cells that home
to the ischemic site (Tepper et al., 2005). In vitro experi-
ments have demonstrated that MSCs are capable of differ-
entiating into vessel forming endothelial cells suggesting that
they may contribute to postnatal vasculogenesis during the
wound healing process. When cultured in medium supple-
mented with VEGF, MSCs exhibit an endothelial-like pheno-
type such as expression of the vascular markers von Willebrand
Factor (vWF), kinase insert domain receptor (KDR), and vas-
cular cell adhesion molecule (VCAM). Furthermore, these
MSCs form tube-like structures when cultured on Matrigel, an
established in vitro model for neovessel formation (Oswald et al.,
2004).
Similar evidence for endothelial differentiation has been
extended to animal models. In a parabiosis model, GFP+ MSCs
were found to traffic from the bone marrow to ischemic wounds
and engraft into neovessels. Approximately 12% of all endothe-
lial cells within the wound bed were determined to originate
from donor MSCs (Hamou et al., 2009). Similar wound heal-
ing studies report the incidence of MSC-derived endothelial cells
ranging from 0.1% to 13% (Badiavas et al., 2003; Fathke et al.,
2004; Sasaki et al., 2008). MSC-treated excisional wounds in
BALB/c mice demonstrated nearly two times the capillary den-
sity as quantified by CD31 staining than vehicle and fibroblast-
treated wounds. In this study, engrafted MSCs were located in the
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perivascular space as opposed to the endothelium suggesting dif-
ferentiation into pericytes. These cells do not directly incorporate
into neovessels but are proposed to participate in angiogene-
sis by guiding endothelial sprouts (Nehls et al., 1992). Current
research is elucidating how pericytes continue to support and reg-
ulate mature vessels through local secretion of soluble growth
factors and mechanical signaling (Hirschi and D’Amore, 1997;
Gerhardt and Betsholtz, 2003; Wu et al., 2007; Rustad et al.,
2012).
MSC-MEDIATED PARACRINE SIGNALING ENHANCES
WOUND REPAIR
There is growing evidence to suggest that MSCs may elicit the
majority of their wound healing properties via paracrine mecha-
nisms. When compared to dermal fibroblasts, which are normally
the main source of growth factors during cutaneous wound heal-
ing, MSCs express significantly greater amounts of VEGF-A,
epidermal growth factor (EGF), erythropoietin, and stromal cell-
derived factor -1α (SDF-1α) (Chen et al., 2008). The same group
demonstrated that soluble proteins secreted by MSCs are potent
mitogens. For example, keratinocytes and endothelial cells exhibit
significantly greater proliferation rates when cultured in condi-
tioned medium fromMSCs compared to medium from fibroblast
cultures. These proteins are also powerful chemoattractants and
promote the migration of inflammatory cells, endothelial cells,
and keratinocytes (Chen et al., 2008). Paracrine factors from
MSCs have also been shown to stimulate collagen secretion from
dermal fibroblasts in vitro (Kim et al., 2007). Excisional wounds
treated with conditioned medium alone from MSC cultures
demonstrate accelerated closure in wild-type mice, corroborating
the importance of MSC-secreted factors in wound healing. These
wounds also exhibited increased recruitment of macrophages, key
cells in the acute healing process, and CD34+ and c-kit+ cells
which have been described as the putative endothelial progenitor
cell (Chen et al., 2008).
OPTIMIZING DELIVERY OF MSCs TO CUTANEOUSWOUNDS
As evidence for the wound healing capacity of MSCs continues
to grow, research has now shifted toward modalities to optimize
cell delivery as studies have shown that the clinical effectiveness
of MSC-therapy is dependent on the number of cells delivered
(Falanga et al., 2007). Most studies have utilized the technically
simple method of injecting a cell suspension intradermally into or
around the wound defect. As described, this method has demon-
strated enhanced wound healing, however, the true therapeutic
potential of MSCs appears to be limited due to poor engraft-
ment efficiency and cell retention at the wound site (Freyman
et al., 2006). Causes of this phenomenon are still under inves-
tigation with evidence suggesting that the hostile wound envi-
ronment may impede high MSC engraftment in acute wounds.
Elevated levels of reactive oxygen species such as those found in
ischemic wounds are thought to impede cell engraftment in tis-
sue (Angelos et al., 2006; Yao et al., 2006). In addition, the shear
forces generated by the injection process itself may lead to anoikis
(Rustad et al., 2012). Alternative delivery systems are therefore
being investigated to enhance MSC function within non-healing
wounds (Figure 2).
Falanga et al. utilized a fibrin spray system to topically admin-
ister autologous MSCs to non-healing lower extremity wounds in
human subjects. Stem cells were found to survive within the fibrin
layer and migrate into the wound tissue. One subject demon-
strated no improvement, four had an average 40% reduction in
wound size, and one subject had complete closure of a wound
that had previously existed for over 10 years (Falanga et al.,
2007).
Building on the idea of providing a scaffolding and exter-
nal niche from the ischemic tissue, Yoshikawa et al. developed
a composite graft combining a commercially available colla-
gen matrix with cultured autologous MSCs. Grafts were applied
to 20 patients with intractable dermatopathies due to thermal
burns, traumatic wounds, and decubitus ulcers. Thirteen of the
20 wounds demonstrated regeneration of fibrous and fat tissue
and underwent re-epithelialization resulting in complete wound
closure. Treatment with the composite graft led to sufficient gran-
ulation tissue and dermal regeneration to allow for successful
skin grafting in an additional five wounds (Yoshikawa et al.,
2008).
Hydrogels are synthetic biomaterials that emulate the hygro-
scopic nature of extracellular matrix making them an ideal
vehicle for MSC delivery (Lutolf and Hubbell, 2005). A novel
collagen-pullulan hydrogel that is non-cytotoxic and provides
protection from oxidative stress was recently described (Wong
et al., 2011a). MSCs seeded and cultured in this hydrogel demon-
strate significantly greater expression of the stemness genes Oct-4,
SOX2, and KLF4 compared to cells plated on standard two-
dimensional culture dishes. Secretion of the wound healing and
angiogenic cytokines MCP1 and VEGF-A are also found to be
increased. Topical hydrogel delivery of MSCs demonstrated sig-
nificantly accelerated wound closure and improved quality of
cutaneous regeneration with greater return of hair follicles and
sebaceous glands when compared to intradermal injection strate-
gies. The number of MSCs found within the wound tissue was
nearly three times greater at day 7 post-wounding and nearly
10 times greater at day 10 in animals receiving the seeded
hydrogen compared to local injection. Co-localization analy-
sis of healed wounds revealed a small percentage (12.5%) of
MSCs expressing the endothelial cell marker CD31 represent-
ing cells directed toward angiogenesis. The vast majority of
engrafted cells differentiated into dermal fibroblasts and peri-
cytes suggesting the wound healing effects were largely secondary
to enhanced secretion of paracrine factors. Indeed, levels of
VEGF, FGF1, MMP8, and MMP9 were all found to be signifi-
cantly higher in tissue from wounds treated with MSCs deliv-
ered by hydrogel versus intradermal injection (Rustad et al.,
2012).
HETEROGENEITY IN MSC PREPARATIONS
Despite the data supporting the potential of MSC-based therapy
for wound repair, controversy remains. The reported contribu-
tion of MSC engraftment to wound repair varies widely in the
literature with some authors reporting little to no evidence of
cellular engraftment (Duffield et al., 2005; Rustad et al., 2012).
The reason for these discrepancies is likely multi-factorial with
cell population heterogeneity being a possible contributor. Clonal
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FIGURE 2 | Strategies for mesenchymal stem cell delivery to cutaneous
wounds. Traditional techniques include local injection of cells into the soft
tissue, direct topical application, and systemic delivery via injection into the
peripheral circulation. These methods have resulted in improved wound
healing but are limited by sub-optimal cell survival and engraftment. Novel
delivery methods are being developed utilizing tissue scaffolds to optimize
stem cell function and maximize the therapeutic potential for cellular
therapy.
studies have demonstrated that even with identical isolation and
expansion methods, MSC isolation by the traditional plastic
adherence technique results in cells that are functionally heteroge-
nous with varying capacities of differentiation (Phinney et al.,
1999). Previous studies have also used MSCs from various culture
passages, however, investigators have shown that MSCs exhibit
different gene expression profiles as they undergo serial pas-
sage (Gregory et al., 2005). In addition, MSC function is highly
dependent on cues from the culture condition therefore differ-
ent seeding densities and growth media utilized by investigators
add to the heterogeneity of cell preparations used in these studies.
These issues speak to the importance of establishing a standard-
ized language when isolating and defining MSCs in the literature
and the need for a method of prospective isolation by specific cell
surface markers.
IMMUNOMODULATORY PROPERTIES OF MSCs
An important property of MSCs which has been demonstrated
both in vitro and in vivo is the immunosuppressive effect elicited
by allogeneic cells. Human MSCs have been shown to suppress
CD4+ and CD8+ T-cell proliferation through the secretion of
soluble factors including hepatocyte growth factor (Di Nicola
et al., 2002) and alter the cytokine secretion profiles of den-
dritic cells, effector T-cells, and natural killer cells to more anti-
inflammatory phenotypes (Aggarwal and Pittenger, 2005). This
phenomenon has been exploited to use MSC-therapy to help treat
skin graft rejection and graft-versus-host disease (Bartholomew
et al., 2002; Le Blanc et al., 2004). How this property may affect
the role of MSCs in wound healing has yet to be fully investi-
gated. Some authors have anecdotally theorized that the beneficial
effects of MSC therapy on cutaneous repair may in part be
due to the prevention or reversal of chronic inflammation. The
possible negative side effects of immunosuppression also raise
questions that continue to be investigated concerning increased
tumorigenicity of cancer cells in animals receiving MSC injec-
tions (Djouad et al., 2003). Further work in understanding the
systemic effects of MSC are certainly required especially if the use
of allogeneic cells is to be considered a clinical possibility.
CONCLUSIONS AND FUTURE WORK
The possible benefits of MSC-based therapy in the clinically
important area of chronic wounds have been demonstrated in
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numerous studies. Administration of MSCs has been shown to
augment the acute inflammatory response, enhances angiogene-
sis, accelerates re-epithelialization, and increases wound strength.
More importantly, these effects have been observed in clinically
relevant conditions of impaired healing such as diabetes.
Although these preliminary findings are promising, several
areas require further investigation before large-scale randomized
human studies can become feasible. Although the International
Society for Cellular Therapy has published minimum crite-
ria to define human MSCs, significant heterogeneity certainly
exists within this population (Dominici et al., 2006). Researchers
have typically utilized plastic adherence to isolate MSCs in cul-
ture, however, macrophages, lymphocytes, endothelial cells, and
smooth muscle cells also adhere to plastic and may contaminate
early passage populations (Deans and Moseley, 2000). Even in
late passage MSCs, cells display morphological and functional
heterogeneity (Javazon et al., 2004). Identifying these various
subpopulations, understanding their phenotypic properties, and
developing methods for prospective isolation by surface marker
profiles will be a crucial step in optimizing directed therapy. Also,
it remains to be elucidated if the primary contribution of MSCs
to cutaneous regeneration is by cellular differentiation or indi-
rectly through paracrine activity. A better understanding of the
mechanism of action is needed to develop more efficient treat-
ment strategies. Long-term systemic effects of MSC-therapy have
yet to be fully established. Limited data has suggested that the
immunosuppressive properties of MSCs could increase suscepti-
bility to malignancies and opportunistic infections (Djouad et al.,
2003; Sundin et al., 2006). Additionally, although no instances
have been reported in humans, BM-MSCs have been shown
to be able to differentiate into carcinoma-associated fibroblasts
and sarcomas (Tolar et al., 2007; Mishra et al., 2008). Finally,
further investigation into delivery methods specifically designed
for the delivery progenitor cells to chronic wounds is neces-
sary to maximize the regenerative properties of MSC-based cell
therapy.
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